Newco Annias debuts with glioblastoma vaccine

Immuno-oncology newco Annias Immunotherapeutics Inc. (Chapel Hill, N.C.) debuted with IP licensed from Duke University to a clinical-stage vaccine that targets solid tumors and a method to boost the vaccine's activity.

CEO Reiner Laus told BioCentury the vaccine targets a strain of cytomegalovirus (CMV) harbored in many solid tumors, while the preconditioning tetanus vaccine booster primes the immune system for the therapy via a local immune reaction at the injection site. ...